Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2021
Price :
$35
*
At a glance
- Drugs MEDI 7352 (Primary) ; MEDI 7352 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2020 Planned number of patients changed from 125 to 132.